InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,447.87
(
-0.31%
)
US TECH 100
18,964.00
(
-1.27%
)
Dow Jones
39,411.21
(
0.67%
)
Brent Oil
85.28
(
1.49%
)
Bitcoin
59,320.95
(
-6.08%
)
Post# of 252332
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119908
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pi post# 58798

Saturday, 02/09/2008 4:24:23 PM

Saturday, February 09, 2008 4:24:23 PM

Post# of 252332
Re: Pre-dosing with drug to screen patients for trials

>The closest analogy to the design I was suggesting is the trial that Pfizer used for Maraviroc where the patients were screened by a tropism assay (from Monogram) and only those that responded went on to Maraviroc dosing, the non-responders were not included in the dosing.<

In the maraviroc trial, patients were pretested for the relevant mutation, not for a clinical response to the drug in question.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up